

A high-angle, top-down photograph of a large group of approximately 50-60 people of various ages, ethnicities, and genders. They are standing on a plain white surface, arranged in a loose, circular formation. The people are wearing a wide variety of colorful clothing, including t-shirts, blouses, dresses, and pants. The lighting is bright and even, casting soft shadows on the ground. The overall composition is centered and symmetrical, emphasizing the diversity and unity of the group.

**RECRUITMENT FEASIBILITY....  
EASY DIVIDE BY 2!**



**AIM OF TODAY**

# Overview of session




# Centre for Drug Development (CDD)

- Ca 30 drug development projects
- 12 clinical trials open, 13 agents in preclinical development
- Combination of agents from academia & industry
- Clinical Development Partnerships

**“STRONG FOCUS ON  
PERFORMING EXCELLENT  
SCIENCE”**

Immatics biotechnologies  
GmbH



CANCER  
RESEARCH  
UK

CENTRE  
FOR DRUG  
DEVELOPMENT

# Combinations Alliance

Increase the number of combination trials in the UK

- 7 partners
- 9 clinical trials running
- Further 4 in set-up
- 2 in close down
- Engaging ECMC network

[www.ecmcnetwork.org.uk/ca](http://www.ecmcnetwork.org.uk/ca)




# Reasons to get it right

1. Patient Benefit
2. Science moves quickly – need to stay relevant
3. Resource, financial and drug supply planning
4. Reputation


# Some Reasons why Early Phase Studies Present a Challenge

1. Highly selected patient population
2. Generally sick patients, heavily pre-treated
3. Protocol design, competitive recruitment, DLT evaluation period
4. Intensive schedule of assessments & PK/PD
5. Specialist centres limiting the choice
6. Emerging safety data that has impact on the protocol

# Leaky pipe



# Want to avoid



**CONTACT US (OR OTHER  
NETWORK COLLEAGUE)  
...THANK YOU**

[www.ecmcnetwork.org.uk/ca](http://www.ecmcnetwork.org.uk/ca)

[combinationsalliance@cancer.org.uk](mailto:combinationsalliance@cancer.org.uk)